Kymera Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	105	39.21	47.07	78.59	46.83	72.83
Revenue Growth	134.84%	-16.70%	-40.11%	67.84%	-35.71%	114.00%
Cost of Revenue	375.57	316.57	240.25	189.08	164.25	137.02
Gross Profit	-270.57	-277.36	-193.18	-110.49	-117.42	-64.19
Selling, General & Admin	75.76	68.19	63.53	55.04	43.83	36.35
Operating Expenses	75.76	68.19	63.53	55.04	43.83	36.35
Operating Income	-346.32	-345.54	-256.71	-165.53	-161.26	-100.53
Interest Expense	-0.34	-0.37	-0.25	-0.2	-0.18	-0.18
Interest & Investment Income	50.91	38.42	38.03	18.76	6.62	0.49
EBT Excluding Unusual Items	-295.75	-307.5	-218.93	-146.96	-154.81	-100.22
Asset Writedown	-3.86	-3.86	-4.93	-	-	-
Pretax Income	-299.6	-311.35	-223.86	-146.96	-154.81	-100.22
Net Income	-299.6	-311.35	-223.86	-146.96	-154.81	-100.22
Net Income to Common	-299.6	-311.35	-223.86	-146.96	-154.81	-100.22
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	93	84	75	58	54	48
Shares Outstanding (Diluted)	93	84	75	58	54	48
Shares Change	17.71%	12.59%	28.58%	8.22%	12.39%	176.60%
EPS (Basic)	-3.21	-3.69	-2.98	-2.52	-2.87	-2.09
EPS (Diluted)	-3.21	-3.69	-2.98	-2.52	-2.87	-2.09
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-237.96	-234.34	-207.34	-137.31	-155.92	-130.54
Free Cash Flow Per Share	-2.55	-2.77	-2.76	-2.35	-2.89	-2.72
Gross Margin	-257.69%	-	-	-140.59%	-250.76%	-88.13%
Operating Margin	-329.83%	-881.24%	-545.36%	-210.62%	-344.37%	-138.03%
Profit Margin	-285.33%	-794.04%	-475.56%	-186.99%	-330.60%	-137.60%
Free Cash Flow Margin	-226.63%	-597.64%	-440.47%	-174.71%	-332.98%	-179.24%
EBITDA	-339.89	-338.83	-250.74	-163.47	-159.48	-99.03
EBITDA Margin	-	-	-	-207.99%	-	-135.97%
D&A For EBITDA	6.43	6.71	5.97	2.07	1.78	1.5
EBIT	-346.32	-345.54	-256.71	-165.53	-161.26	-100.53
EBIT Margin	-	-	-	-210.62%	-	-138.03%

SEC Filings: 10-K · 10-Q